Lavender Oil Medipha
Lavandula angustifolia essential oil (Silexan) – soft capsules for anxiety relief
Quick Facts About Lavender Oil Medipha
Key Takeaways About Lavender Oil Medipha
- Clinically proven anxiolytic: Multiple randomized controlled trials demonstrate efficacy comparable to lorazepam in treating generalized anxiety disorder (GAD)
- No sedation or dependence: Unlike benzodiazepines, Silexan does not cause drowsiness, impair driving ability, or lead to tolerance or withdrawal symptoms
- Simple dosing: One 80 mg soft capsule taken once daily, with or without food, provides consistent anxiety relief
- Well-tolerated: The most common side effect is mild gastrointestinal discomfort such as burping with a lavender taste; serious adverse effects are rare
- Mechanism of action: Works by modulating voltage-dependent calcium channels and the serotonin transporter, a distinct mechanism from conventional anxiolytics
What Is Lavender Oil Medipha and What Is It Used For?
Lavender Oil Medipha is a herbal medicine containing Silexan, a standardized essential oil preparation from Lavandula angustifolia (narrow-leaved lavender). It is used for the symptomatic relief of generalized anxiety disorder (GAD), restlessness, and nervous tension. Clinical trials have demonstrated anxiolytic efficacy comparable to some conventional medications.
Lavender Oil Medipha belongs to the category of herbal anxiolytics – plant-based medicines used to relieve anxiety. The active ingredient, Silexan, is a proprietary preparation of essential oil extracted from the flowering tops of Lavandula angustifolia through steam distillation. It is standardized to contain specific concentrations of linalool and linalyl acetate, the primary pharmacologically active compounds responsible for its therapeutic effects.
The product is formulated as soft gelatin capsules, each containing 80 mg of the lavender oil preparation. The soft capsule formulation ensures consistent bioavailability and protects the volatile essential oil components from degradation before reaching the gastrointestinal tract, where absorption occurs. Unlike aromatherapy applications of lavender oil, this oral formulation delivers pharmacologically relevant doses that produce measurable effects on the central nervous system.
Clinical evidence supporting the use of Silexan-based products in anxiety disorders has grown considerably since the early 2010s. Multiple randomized, double-blind, placebo-controlled trials have demonstrated statistically significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores compared to placebo. Notably, a pivotal trial published in Phytomedicine showed that 80 mg of Silexan daily was as effective as 0.5 mg of lorazepam daily in patients with generalized anxiety disorder, without the sedative effects and dependence risk associated with benzodiazepines.
The European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) has evaluated lavender oil preparations and recognizes their use based on clinical evidence for the relief of mild symptoms of mental stress and to aid sleep. In several European countries, Silexan-based products have received marketing authorization as traditional herbal medicinal products or registered herbal medicines for anxiety relief.
Mechanism of action
Silexan exerts its anxiolytic effects through a unique dual mechanism of action. First, it modulates voltage-dependent calcium channels (VDCC), particularly the N-type and P/Q-type channels in presynaptic nerve terminals. By reducing calcium influx into neurons, Silexan decreases neuronal excitability and the release of excitatory neurotransmitters, thereby calming overactive neural circuits associated with anxiety.
Second, Silexan has been shown to inhibit the serotonin transporter (SERT), the same molecular target of SSRI antidepressants. This serotonergic activity may contribute to its mood-stabilizing and anxiolytic properties. Importantly, unlike benzodiazepines, Silexan does not act on GABA-A receptors. This means it produces calming effects without sedation, cognitive impairment, muscle relaxation, or the risk of dependence and withdrawal that characterize benzodiazepine use.
Pharmacokinetic studies show that Silexan reaches peak plasma concentrations within 1 to 3 hours after oral administration. It is metabolized primarily in the liver via the cytochrome P450 enzyme CYP3A4. The main metabolites are subsequently excreted in the urine. The elimination half-life allows for once-daily dosing, which simplifies the treatment regimen and supports adherence.
The absence of GABAergic activity is a key differentiator from conventional anxiolytics. Because Silexan does not interact with GABA receptors, there is no risk of cross-tolerance with alcohol, no potentiation of CNS depressant effects, and no withdrawal syndrome upon discontinuation – making it a particularly favorable option for patients who are concerned about dependence or for whom benzodiazepines are contraindicated.
What Should You Know Before Taking Lavender Oil Medipha?
Before taking Lavender Oil Medipha, inform your doctor if you are pregnant, breastfeeding, taking other medications (especially CNS-active drugs or anticoagulants), or have a history of liver disease. This medicine is not recommended for children under 18 years of age due to insufficient safety data.
While Lavender Oil Medipha has a favorable safety profile compared to many conventional anxiolytics, there are important considerations that patients and healthcare providers should be aware of before initiating treatment. A thorough medical history and review of concurrent medications is essential to ensure safe and effective use of this herbal medicinal product.
Contraindications
Lavender Oil Medipha should not be used by individuals who have a known hypersensitivity (allergy) to lavender oil, Lavandula angustifolia, or any of the excipients contained in the soft capsule formulation. Allergic reactions to lavender are uncommon but can manifest as contact dermatitis, urticaria, or, in very rare cases, anaphylaxis. If you have ever experienced an allergic reaction to lavender-scented products, perfumes, or essential oils, discuss this with your doctor before taking this medicine.
This product is not recommended for use in children and adolescents under 18 years of age, as clinical trial data in this population is insufficient to establish safety and efficacy. The pharmacokinetic profile and dose-response relationship in pediatric populations have not been adequately characterized.
Warnings and precautions
Patients with pre-existing liver disease or hepatic impairment should exercise caution when using Lavender Oil Medipha. Since Silexan is metabolized primarily via CYP3A4 in the liver, impaired hepatic function may alter the drug's metabolism, potentially leading to higher plasma concentrations and an increased risk of adverse effects. Liver function monitoring may be advisable in patients with known hepatic conditions.
Although Silexan does not typically cause drowsiness, individual responses may vary. During the initial period of treatment, patients should be aware of how the medicine affects them before engaging in activities that require full alertness. However, clinical trials have consistently shown no impairment of psychomotor function, reaction time, or driving ability.
If symptoms of anxiety persist or worsen after two weeks of treatment, patients should consult their healthcare provider. Generalized anxiety disorder can be a complex condition that may require multimodal treatment approaches, including psychotherapy, lifestyle modifications, or conventional pharmacotherapy in combination with or instead of herbal treatment.
Lavender Oil Medipha is intended for the symptomatic relief of anxiety and is not a substitute for professional psychiatric care in cases of severe anxiety, panic disorder, or anxiety associated with depression or suicidal ideation. If you experience persistent low mood, thoughts of self-harm, or significant functional impairment, seek immediate medical attention.
Pregnancy and breastfeeding
The safety of Lavender Oil Medipha during pregnancy has not been established through adequate clinical studies. As a precautionary measure, use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus. Animal reproductive toxicity studies with Silexan have not shown teratogenic effects at therapeutic doses, but human data are insufficient to draw definitive conclusions.
It is unknown whether Silexan or its metabolites are excreted in human breast milk. Due to the lack of data, breastfeeding mothers should avoid using Lavender Oil Medipha or should discontinue breastfeeding during treatment, after consultation with their healthcare provider. The decision to continue or discontinue breastfeeding versus treatment should consider the benefit of breastfeeding to the infant alongside the benefit of therapy to the mother.
Driving and operating machinery
Clinical studies have not demonstrated any impairment of psychomotor function or driving ability with Silexan at the recommended dose. In a double-blind, placebo-controlled study specifically designed to assess driving performance, Silexan 160 mg (twice the standard dose) did not impair driving ability as measured by standardized driving simulation tests. This is in stark contrast to benzodiazepines and many other anxiolytics, which significantly impair driving performance even at therapeutic doses.
How Does Lavender Oil Medipha Interact with Other Drugs?
Lavender Oil Medipha is metabolized by CYP3A4 and may theoretically interact with drugs that inhibit or induce this enzyme. It may enhance the effects of CNS depressants and serotonergic drugs. No serious drug interactions have been reported in clinical trials, but concurrent use with anticoagulants, SSRIs, or sedatives should be discussed with a healthcare provider.
Drug interaction potential with Lavender Oil Medipha is generally considered low based on available clinical evidence. However, because the active ingredient Silexan is metabolized via the hepatic cytochrome P450 enzyme system, specifically CYP3A4, theoretical interactions with other substrates, inhibitors, or inducers of this enzyme pathway are possible. Healthcare providers and patients should be aware of these potential interactions to ensure safe concurrent medication use.
In vitro studies have shown that Silexan can inhibit CYP3A4 at high concentrations, although the clinical relevance of this finding at standard therapeutic doses (80 mg daily) appears to be limited. Nonetheless, caution is advised when combining Lavender Oil Medipha with medications that have a narrow therapeutic index and are primarily metabolized by CYP3A4, such as certain immunosuppressants, anticoagulants, and antiarrhythmics.
Major interactions
| Drug/Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Benzodiazepines (diazepam, lorazepam) | Pharmacodynamic – additive CNS effects | Potential enhanced sedation and anxiolysis | Monitor closely; dose adjustment may be needed |
| SSRIs/SNRIs (sertraline, venlafaxine) | Pharmacodynamic – serotonergic activity | Theoretical risk of serotonin-related effects | Inform prescriber; monitor for serotonergic symptoms |
| Anticoagulants (warfarin) | Pharmacokinetic – CYP3A4 interaction | Possible altered anticoagulant effect | Monitor INR; adjust warfarin dose if needed |
| CYP3A4 inhibitors (ketoconazole, clarithromycin) | Pharmacokinetic – reduced metabolism | Increased Silexan plasma levels | Use with caution; consider dose reduction |
Minor interactions
| Drug/Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Antihypertensives | Pharmacodynamic – mild | Possible mild additive blood pressure lowering | Monitor blood pressure initially |
| CYP3A4 inducers (rifampicin, carbamazepine) | Pharmacokinetic – increased metabolism | Possibly reduced efficacy of Silexan | Consider increased frequency of monitoring |
| Alcohol | Pharmacodynamic | No significant interaction demonstrated in studies | No specific restriction; moderate use advised |
It is important to note that despite these theoretical interactions, clinical trials of Silexan that included patients taking concurrent medications (including SSRIs, antihypertensives, and oral contraceptives) did not report clinically significant drug interactions at the standard 80 mg daily dose. Nevertheless, patients should always inform their healthcare provider about all medications they are taking, including over-the-counter drugs, herbal products, and dietary supplements.
What Is the Correct Dosage of Lavender Oil Medipha?
The standard dosage of Lavender Oil Medipha is one 80 mg soft capsule taken once daily by mouth. Swallow the capsule whole with a glass of water. It can be taken with or without food. No dose titration is required. Treatment duration should be discussed with your healthcare provider.
Lavender Oil Medipha has a straightforward dosing regimen that supports patient compliance. Unlike many anxiolytic medications that require gradual dose titration, Silexan can be started at its full therapeutic dose from the first day of treatment. Clinical trials have demonstrated that the onset of anxiolytic effects typically begins within the first one to two weeks of treatment, with continued improvement over subsequent weeks.
Adults
Standard adult dosage
Dose: 80 mg (one soft capsule) once daily
Administration: Swallow whole with a glass of water, with or without food
Timing: Can be taken at any time of day, though taking it at a consistent time is recommended
Duration: Initial treatment period of 6–10 weeks is typical in clinical trials; longer-term use should be under medical supervision
In clinical trials, some studies have also investigated a dose of 160 mg daily (two capsules). While the higher dose showed additional efficacy benefits in some measures, particularly in patients with more severe anxiety, the standard recommended dose remains 80 mg daily for most patients. The higher dose did not result in a proportional increase in adverse effects, suggesting a favorable dose-response relationship. Any dose adjustment should be made by the prescribing healthcare provider.
Children
Pediatric dosage
Not recommended. The safety and efficacy of Lavender Oil Medipha in children and adolescents under 18 years of age has not been established. Clinical trials have not included sufficient numbers of pediatric patients to allow dosing recommendations. Parents or caregivers should consult a pediatric psychiatrist or pediatrician for appropriate anxiety management in children.
Elderly
Elderly dosage (65 years and older)
Dose: 80 mg (one soft capsule) once daily – no dose adjustment required
Clinical trials have included elderly patients and have not shown a need for dose reduction based on age alone. However, elderly patients are more likely to have concurrent hepatic or renal impairment and may be taking multiple medications, so individual assessment is advisable. The absence of sedative effects makes Silexan a particularly attractive option for elderly patients, in whom sedation-related falls are a significant concern with conventional anxiolytics.
Missed dose
If you forget to take a dose of Lavender Oil Medipha, take it as soon as you remember on the same day. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. The steady-state pharmacokinetics of Silexan mean that missing a single dose is unlikely to significantly impact the overall therapeutic effect, provided that the medication is taken consistently on most days.
Overdose
There is limited clinical data regarding overdose with Silexan. In clinical trials, doses of up to 160 mg daily were well tolerated. Based on the available safety data, an accidental overdose of Lavender Oil Medipha is unlikely to cause serious adverse effects. Possible symptoms of overdose may include gastrointestinal discomfort, nausea, and headache.
In the event of a suspected overdose, seek medical attention or contact your local poison control center. Treatment would be symptomatic and supportive, as no specific antidote exists. Due to the relatively low toxicity profile of Silexan, aggressive decontamination measures such as gastric lavage are unlikely to be necessary except in cases of massive ingestion.
No cases of life-threatening overdose with Silexan have been reported in the published literature. The wide therapeutic margin and absence of GABAergic activity mean that respiratory depression, a primary concern with benzodiazepine and barbiturate overdose, is not expected with Silexan overdose.
What Are the Side Effects of Lavender Oil Medipha?
The most common side effect of Lavender Oil Medipha is gastrointestinal discomfort, particularly burping with a lavender taste (eructation). Other possible side effects include nausea, abdominal pain, and allergic skin reactions. Serious adverse effects are rare. Unlike benzodiazepines, Silexan does not cause drowsiness, cognitive impairment, or dependence.
Lavender Oil Medipha has demonstrated a favorable safety profile in clinical trials. The overall incidence of adverse events was only slightly higher than placebo in controlled studies, and most reported side effects were mild and transient. The most distinctive side effect is related to the essential oil nature of the active ingredient – a lavender-flavored eructation (burping) that some patients experience after taking the capsule.
It is important to distinguish between side effects and symptoms of the underlying anxiety condition. Many symptoms commonly associated with anxiety (such as nausea, headache, and gastrointestinal disturbance) overlap with potential side effects of Lavender Oil Medipha, which can complicate attribution in clinical practice. If you experience any new or worsening symptoms while taking this medicine, consult your healthcare provider for evaluation.
Common
May affect up to 1 in 10 people
- Eructation (burping) with lavender taste
- Nausea
- Abdominal discomfort or pain
- Dyspepsia (indigestion)
Uncommon
May affect up to 1 in 100 people
- Headache
- Dizziness
- Constipation or diarrhea
- Dry mouth
- Flatulence
Rare
May affect up to 1 in 1,000 people
- Allergic skin reactions (rash, urticaria, pruritus)
- Contact dermatitis
- Fatigue
- Palpitations
The burping side effect deserves special mention as it is the most frequently cited reason for treatment discontinuation. It occurs because the essential oil is released from the soft capsule as it dissolves in the stomach, producing a distinctive lavender flavor that can be detected during eructation. Taking the capsule with food or taking it just before bedtime may help reduce the frequency and intensity of this side effect. Some patients find that the symptom diminishes after the first few days of treatment as the body adjusts.
In long-term studies (up to 10 weeks), no new or unexpected safety signals emerged. Importantly, no evidence of hepatotoxicity, hematological abnormalities, or cardiovascular adverse effects has been observed in clinical trials. Laboratory parameters including liver function tests, kidney function tests, and complete blood counts remained within normal ranges throughout treatment in controlled studies.
Although extremely rare, seek immediate medical attention if you experience signs of a severe allergic reaction such as swelling of the face, lips, tongue, or throat; difficulty breathing; widespread skin rash with itching; or feeling faint. Discontinue the medicine and contact your healthcare provider immediately.
How Should You Store Lavender Oil Medipha?
Store Lavender Oil Medipha below 25°C (77°F) in the original packaging to protect from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of Lavender Oil Medipha is essential to maintain the potency and quality of the lavender oil active ingredient. As a product containing volatile essential oil compounds, it is particularly sensitive to environmental conditions that can cause degradation of the active constituents. The soft gelatin capsule formulation provides a barrier against oxidation, but additional precautions should be observed.
Store the capsules at a temperature not exceeding 25°C (77°F). Avoid storing the product in hot environments such as near radiators, in direct sunlight, or in a car during warm weather. High temperatures can cause the soft gelatin capsule to soften, become sticky, or release the oil prematurely. If capsules appear discolored, misshapen, or have leaked, they should not be used.
Keep the capsules in their original packaging (blister pack or container) until the time of use. This protects them from light and moisture, both of which can degrade the essential oil components. Do not transfer capsules to other containers unless those containers provide equivalent protection from light and humidity.
As with all medicines, keep Lavender Oil Medipha out of reach and sight of children. The soft capsules may be visually appealing to young children due to their size and appearance. Store the product in a locked medicine cabinet or a location that is not accessible to children.
Check the expiry date on the packaging before each use. Do not use Lavender Oil Medipha after the expiry date. Expired essential oil preparations may have diminished potency or altered composition due to chemical changes in the volatile compounds over time. Unused or expired capsules should be returned to a pharmacy for proper disposal and should not be flushed down the toilet or disposed of in household waste, in accordance with local pharmaceutical waste regulations.
What Does Lavender Oil Medipha Contain?
Each Lavender Oil Medipha soft capsule contains 80 mg of Silexan (Lavandula angustifolia essential oil) as the active ingredient. The soft capsule shell is made of gelatin, glycerol, and other excipients. The oil preparation is standardized to contain defined concentrations of linalool and linalyl acetate.
Active ingredient
The active substance in Lavender Oil Medipha is Silexan, a patented preparation of essential oil obtained by steam distillation from the flowering tops of Lavandula angustifolia Mill. (narrow-leaved lavender, also known as English lavender or true lavender). Each soft capsule contains 80 mg of this preparation.
Silexan is standardized to contain specific proportions of its key pharmacologically active components:
- Linalool (25–38%): A monoterpenoid alcohol that is the primary anxiolytic component, responsible for modulating voltage-dependent calcium channels
- Linalyl acetate (25–45%): An ester of linalool that contributes to the overall pharmacological activity and stability of the preparation
- Additional terpene compounds including lavandulyl acetate, terpinen-4-ol, and 1,8-cineole in smaller quantities
The standardization of these components ensures batch-to-batch consistency in the finished product, which is critical for reliable clinical outcomes. This distinguishes pharmaceutical-grade lavender oil preparations from the highly variable essential oil products available in the consumer marketplace, which may contain different lavender species or inconsistent concentrations of active compounds.
Excipients (inactive ingredients)
The soft capsule shell and other inactive components may include:
- Gelatin: Forms the soft capsule shell
- Glycerol (E422): Plasticizer for the gelatin shell
- Sorbitol solution (E420): Humectant and stabilizer
- Medium-chain triglycerides: Carrier oil to ensure uniform distribution of the essential oil within the capsule
- Rapeseed oil: Additional carrier oil
- Iron oxide (E172): Coloring agent for the capsule shell
- Titanium dioxide (E171): Opacifier for the capsule shell (note: this excipient has been reassessed by EFSA and may be removed from future formulations in some markets)
Patients with known allergies to any of these excipients should inform their healthcare provider before starting treatment. The product contains gelatin, which is derived from animal sources and may not be suitable for vegetarian or vegan patients. It also contains sorbitol, which may cause gastrointestinal symptoms in patients with rare hereditary fructose intolerance.
Frequently Asked Questions About Lavender Oil Medipha
Lavender Oil Medipha is a herbal medicine used for the symptomatic relief of generalized anxiety disorder (GAD) and restlessness. It contains Silexan, a standardized lavender oil preparation that has been shown in clinical trials to reduce anxiety symptoms comparable to some conventional medications, without causing sedation or dependence. It is taken as one soft capsule (80 mg) once daily.
Lavender Oil Medipha works through a dual mechanism: it modulates voltage-dependent calcium channels (VDCC) to reduce neuronal excitability, and it inhibits the serotonin transporter (SERT) to stabilize mood. Unlike benzodiazepines, it does not act on GABA receptors, which means it provides anxiety relief without sedation, cognitive impairment, or risk of dependence. Peak plasma levels are reached within 1–3 hours after taking the capsule.
While no serious interactions have been reported in clinical trials, Lavender Oil Medipha may theoretically enhance the effects of SSRIs and other serotonergic medications due to its activity on the serotonin transporter. You should inform your doctor about all medications you are taking before starting Lavender Oil Medipha. Your healthcare provider can assess whether the combination is suitable for you and monitor for any additive effects.
No. One of the key advantages of Lavender Oil Medipha over conventional anxiolytics is that it does not cause drowsiness. Clinical studies, including specific driving simulation tests, have confirmed that Silexan does not impair psychomotor function, reaction time, or driving ability, even at doses up to 160 mg (twice the standard dose). This makes it suitable for people who need to remain alert during the day.
Clinical studies of up to 10 weeks have shown a favorable safety profile, and longer-term observational data support continued safety. No evidence of tolerance, dependence, or withdrawal symptoms has been observed. The most common side effect is gastrointestinal discomfort, particularly burping with a lavender taste, which often diminishes over time. However, long-term use should always be supervised by a healthcare provider to ensure continued appropriateness of treatment.
Clinical studies have not demonstrated a significant interaction between Silexan and alcohol. Unlike benzodiazepines, Silexan does not act on GABA receptors, so it does not potentiate the sedative effects of alcohol. However, it is generally advisable to consume alcohol in moderation while taking any medication. Excessive alcohol consumption can worsen anxiety symptoms and may interfere with the therapeutic benefits of treatment.
References & Medical Sources
This article is based on the following evidence-based medical sources. All medical claims are supported by Level 1A evidence (systematic reviews of randomized controlled trials) or authoritative medical guidelines.
- Kasper S, Gastpar M, Müller WE, et al. “Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial.” Int Clin Psychopharmacol. 2010;25(5):277–287.
- Woelk H, Schläfke S. “A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.” Phytomedicine. 2010;17(2):94–99.
- Kasper S, Anghelescu I, Dienel A. “Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep: a randomized, placebo-controlled trial.” Eur Neuropsychopharmacol. 2015;25(11):1960–1967.
- European Medicines Agency (EMA). “Assessment report on Lavandula angustifolia Miller, aetheroleum.” Committee on Herbal Medicinal Products (HMPC). EMA/HMPC/143183/2010.
- Schuwald AM, Noldner M, Wilmes T, et al. “Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels.” PLoS One. 2013;8(4):e59998.
- Kasper S, Volz HP, Dienel A, Schläfke S. “Efficacy of Silexan in mixed anxiety-depression: a randomized, placebo-controlled trial.” Eur Neuropsychopharmacol. 2016;26(2):331–340.
- World Health Organization. “WHO Monographs on Selected Medicinal Plants.” Vol. 3. Geneva: WHO; 2007.
- British National Formulary (BNF). “Herbal medicines and anxiolytics.” NICE Evidence Services. 2024.
- Möller HJ, Volz HP, Dienel A, et al. “Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.” Eur Arch Psychiatry Clin Neurosci. 2019;269(2):183–193.
- Generoso MB, Soares A, Taiar IT, et al. “Lavender Oil Preparation (Silexan) for Treating Anxiety: An Updated Meta-Analysis.” J Clin Psychopharmacol. 2022;42(6):587–592.
About Our Medical Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians and pharmacologists with expertise in clinical pharmacology, psychiatry, and herbal medicine. Our team follows the GRADE evidence framework and adheres to international guidelines from the EMA, WHO, and NICE.
Every article undergoes a rigorous multi-step review process: initial drafting by qualified medical writers, fact-checking against primary sources, clinical accuracy review by specialist physicians, and final editorial review for clarity and accessibility.
We prioritize Level 1A evidence from systematic reviews and meta-analyses of randomized controlled trials. All clinical claims are supported by references to peer-reviewed literature and authoritative medical guidelines.
For more information about our medical team and editorial standards, visit our Medical Team and Editorial Standards pages. If you notice any inaccuracies or have suggestions for improvement, please contact us.